Clinical Trial Update: Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) [Phase 3]

View source ↗

Summary

Open-label extension ADEPT-3 study to evaluate the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's disease. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease with Psychosis

Drugs mentioned

• KarXT (xanomeline-trospium)

Snippet

Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Conditions: Psychosis Associated With Alzheimer's Disease | Phase 3 | Status: RECRUITING